Treatment of co-occurring anxiety disorders and substance use disorders.
Treatment of co-occurring anxiety disorders and substance use disorders.
复制标题
治疗同时发生的焦虑症和药物使用障碍。
DOI：
10.1097/hrp.0000000000000058
复制
发表时间：
2015-03
影响因子：
3.8
通讯作者：
McHugh RK
中科院分区：
文献类型：
--
作者：
McHugh RK
在普通人群和寻求治疗的样本中，焦虑症与物质使用障碍的发生率都很高。这些疾病的共同发生与症状严重程度、残疾程度和病程较差有关。然而，相对较少的研究重点已经给予治疗共存的焦虑和物质使用障碍。研究文献中的这一显著差距不仅可能使焦虑得不到治疗或治疗不足，而且可能增加复发和不良药物使用结果的风险。这篇手稿的目的是提供关于治疗共存的焦虑和物质使用障碍的文献的现状的回顾。这篇综述包括对这种共发生的流行病学的简要概述，在物质使用障碍的背景下评估焦虑的挑战，治疗方法的证据，以及这一研究不足领域的新进展和未来方向。强调了未来研究确定共同发生的焦虑和物质使用障碍的最佳行为和药物治疗的重要性。
Anxiety disorders co-occur with substance use disorders at a high rate in both the general population and in treatment-seeking samples. The co-occurrence of these disorders is associated with greater symptom severity, higher levels of disability, and poorer course of illness relative to either disorder alone. However, relatively little research focus has been afforded to the treatment of co-occurring anxiety and substance use disorders. This notable gap in the research literature may not only leave anxiety untreated or under-treated, but may also increase the risk for relapse and poor substance use outcomes. The aim of this manuscript is to provide a review of the current state of the literature on the treatment of co-occurring anxiety and substance use disorders. This review includes brief overview of the epidemiology of this co-occurrence, challenges in assessing anxiety in the context of a substance use disorder, evidence for treatment approaches, and new advancements and future directions in this understudied area. The importance of future research to identify optimal behavioral and pharmacologic treatments for co-occurring anxiety and substance use disorders is highlighted.